Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) Stock

Share on StockTwits

Syros Pharmaceuticals Inc (NASDAQ:SYRS) major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of Syros Pharmaceuticals stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $7.77, for a total value of $489,510.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

SYRS opened at $7.40 on Friday. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.02. The company has a 50 day simple moving average of $7.18. The firm has a market cap of $322.07 million, a PE ratio of -3.87 and a beta of 1.95. Syros Pharmaceuticals Inc has a 12 month low of $5.17 and a 12 month high of $13.16.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, May 1st. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.08. The business had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.42 million. Syros Pharmaceuticals had a negative return on equity of 74.28% and a negative net margin of 3,012.04%. As a group, sell-side analysts expect that Syros Pharmaceuticals Inc will post -1.79 EPS for the current fiscal year.

Several research analysts have weighed in on SYRS shares. Zacks Investment Research downgraded Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 9th. Piper Jaffray Companies set a $44.00 target price on First Merchants and gave the company a “buy” rating in a research note on Wednesday, April 10th. BidaskClub upgraded Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. HC Wainwright reiterated a “neutral” rating on shares of Syros Pharmaceuticals in a research note on Thursday, May 2nd. Finally, Roth Capital started coverage on Syros Pharmaceuticals in a research note on Friday, July 12th. They issued a “buy” rating and a $17.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $16.03.

Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Arbitrage SA acquired a new stake in shares of Syros Pharmaceuticals in the 1st quarter valued at approximately $48,000. Bank of America Corp DE raised its holdings in Syros Pharmaceuticals by 205.9% during the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after purchasing an additional 11,711 shares during the last quarter. Rhumbline Advisers raised its holdings in Syros Pharmaceuticals by 51.4% during the fourth quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock worth $181,000 after purchasing an additional 10,995 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its holdings in Syros Pharmaceuticals by 8.3% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,380 shares of the company’s stock worth $369,000 after purchasing an additional 3,100 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Syros Pharmaceuticals by 8.9% during the fourth quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock worth $470,000 after purchasing an additional 6,883 shares during the last quarter. 56.16% of the stock is owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Read More: What is a blue-chip stock?

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Set $12.25 Target Price for Cumberland Pharmaceuticals, Inc.
Zacks: Analysts Set $12.25 Target Price for Cumberland Pharmaceuticals, Inc.
Short Interest in Webster Financial Co.  Grows By 20.3%
Short Interest in Webster Financial Co. Grows By 20.3%
WESCO International, Inc.  Short Interest Down 16.4% in July
WESCO International, Inc. Short Interest Down 16.4% in July
Advance Auto Parts  Stock Rating Reaffirmed by Evercore ISI
Advance Auto Parts Stock Rating Reaffirmed by Evercore ISI
AAC  Lowered to “Market Perform” at Raymond James
AAC Lowered to “Market Perform” at Raymond James
SSE  Given Neutral Rating at JPMorgan Chase & Co.
SSE Given Neutral Rating at JPMorgan Chase & Co.


© 2006-2019 Ticker Report